Tag Archive for: antibody-drug conjugate
Phase 1 Trial For BL-M14D1 For Neuroendocrine Cancers
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1/2 Results for MHB088C Antibody-Drug Conjugate for mCRCP
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxA New Potential Treatment For Early Prostate Cancer: TGW101
/0 Comments/in Clinical Trial, Non-Metastatic, Not PCa related, Phase 1/by MaxNext-Generation ADCs for Cancer Treatment with Potential in Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxSDV2102: A Promising ADC That Targets PSMA Expressing Tumors
/0 Comments/in Antibody-Drug Conjugate, Preclinical Research/by MaxTD001: a New Potent ADC for Prostate Cancer Expressing PSMA
/0 Comments/in Antibody-Drug Conjugate, Preclinical Research/by MaxPhase 1 Soon Recruiting: MK-2400 (Ifinatamab Deruxtecan) for Metastatic Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxFG-3246 Advances to Phase 2 Trial in Prostate Cancer After Promising Early Results
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxBR111: A New ADC Therapy That Could Work Also For Prostate Cancer
/0 Comments/in Clinical Trial, Not PCa related/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine Pluvicto prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- LYA914: A Novel Oral PROTAC Targeting Androgen Receptor Variants in Prostate Cancer July 30, 2025
- Phase 1/2 Trial for DS-3939a: A Novel TA-MUC1–Directed ADC for Advanced Prostate Cancer and Beyond July 29, 2025
- AI Platform Aims to Revolutionize Cancer Immunotherapy July 28, 2025
- FDA Clears First-in-Human Phase 1 Trial: RV-01 Targeting Solid Tumors July 28, 2025